07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Naloxone nasal spray regulatory update

Indivior said FDA accepted and granted Priority Review to an NDA for naloxone nasal spray to treat opioid overdose. The company expects a decision from FDA late in 4Q15. Last December, Reckitt Benckiser Group plc...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Naloxone nasal spray regulatory update

AntiOp said FDA granted Fast Track designation for AntiOp’s naloxone nasal spray to aid in the reversal of opioid overdose. The product is in Phase I testing. AntiOp’s nasal formulation is a prefilled, unit-dose, disposable...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

AntiOp, Reckitt Benckiser deal

Reckitt's Reckitt Benckiser Pharmaceuticals Inc. subsidiary partnered with AntiOp to co-develop and commercialize AntiOp's naloxone nasal spray to aid in the reversal of opioid overdose. Reckitt also received an option to acquire all rights to...